Literature DB >> 20309760

Testing gene-treatment interactions in pharmacogenetic studies.

Min He1, Andrew Allen.   

Abstract

Drug-related side effects are one of the leading causes of death and illness in the developed world. Finding genes that modify drug response has the potential to significantly improve drug delivery, by identifying both individuals that can benefit from therapy and those at increased risk of harm. We present a simple approach to testing gene-by-treatment interactions in case-control pharmacogenetic studies. The approach utilizes a retrospective model that seeks to increase power through a Hardy-Weinberg equilibrium assumption among the controls, but does not assume that the event of interest is rare in the target population. We conduct extensive simulations and find that the approach shows similar or improved power, compared to standard methods, in all cases considered. We present methods for both autosomal and X-linked markers and show how the methods can be easily implemented using standard statistical software.

Entities:  

Mesh:

Year:  2010        PMID: 20309760      PMCID: PMC3706096          DOI: 10.1080/10543400903572761

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  11 in total

1.  Pharmacogenomics--drug disposition, drug targets, and side effects.

Authors:  William E Evans; Howard L McLeod
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  Simple methods for assessing haplotype-environment interactions in case-only and case-control studies.

Authors:  L C Kwee; M P Epstein; A K Manatunga; R Duncan; A S Allen; G A Satten
Journal:  Genet Epidemiol       Date:  2007-01       Impact factor: 2.135

3.  Exploiting Hardy-Weinberg equilibrium for efficient screening of single SNP associations from case-control studies.

Authors:  Jinbo Chen; Nilanjan Chatterjee
Journal:  Hum Hered       Date:  2007-02-22       Impact factor: 0.444

4.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.

Authors:  A Kindmark; A Jawaid; C G Harbron; B J Barratt; O F Bengtsson; T B Andersson; S Carlsson; K E Cederbrant; N J Gibson; M Armstrong; M E Lagerström-Fermér; A Dellsén; E M Brown; M Thornton; C Dukes; S C Jenkins; M A Firth; G O Harrod; T H Pinel; S M E Billing-Clason; L R Cardon; R E March
Journal:  Pharmacogenomics J       Date:  2007-05-15       Impact factor: 3.550

5.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

Review 6.  Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research.

Authors:  W Kalow; B K Tang; L Endrenyi
Journal:  Pharmacogenetics       Date:  1998-08

7.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

Review 8.  Pharmacogenomics: unlocking the human genome for better drug therapy.

Authors:  H L McLeod; W E Evans
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 9.  Pharmacogenomics: the inherited basis for interindividual differences in drug response.

Authors:  W E Evans; J A Johnson
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

10.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.

Authors: 
Journal:  Nature       Date:  2007-06-07       Impact factor: 49.962

View more
  2 in total

1.  Genome-Wide Gene-Environment Interaction Analysis Using Set-Based Association Tests.

Authors:  Wan-Yu Lin; Ching-Chieh Huang; Yu-Li Liu; Shih-Jen Tsai; Po-Hsiu Kuo
Journal:  Front Genet       Date:  2019-01-14       Impact factor: 4.599

2.  Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease.

Authors:  Christophe Lenglos; Sue-Jin Lin; Yashar Zeighami; Tobias R Baumeister; Felix Carbonell; Yasser Iturria-Medina
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.